Results of Four Single-Dose Trials of FX-322 Show Improved Speech Perception

Time: 3:15 pm
day: Day Two


• This presentation showcases clinical case studies of FX-322, a small-molecule combination designed to regenerate cochlear hair cells
• This summary combines the results of four single-dose trials of FX-322, three of which showed speech perception improvements in some patients
• These positive results support the continued evaluation of FX-322 in multiple populations to determine the full range of benefit to SNHL patients as a therapeutic for hearing restoration